(ALVO)
0.00
0.00 (0.00%)

0.00
0.00 (0.00%)
Alvotech o'z sho'ba korxonalari orqali butun dunyo bo'ylab bemorlar uchun biosimilar dori vositalarini ishlab chiqadi va ishlab chiqaradi. Kompaniya otoimmün, ko'z va suyak kasalliklari, shuningdek, saraton kasalliklari bo'yicha biosimilar mahsulotlarni taklif etadi. Kompaniyaning asosiy dasturi AVT02 bo'lib, u revmatoid artrit, psoriatik artrit, Kron kasalligi, yarali kolit, blyashka psoriaz va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanishlarni davolash uchun Humiraga o'xshash yuqori konsentratsiyali formulali biosimilar hisoblanadi; AVT04, psoriatik artrit, Kron kasalligi, yarali kolit, blyashka psoriaz va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanishlarni davolash uchun Stelara biosimilaridir; AVT06, yoshi bilan bog'liq makula degeneratsiyasi, makula shishi va diabetik retinopatiya kabi turli xil holatlarni davolash uchun Eylea biosimilaridir; va AVT03, Xgeva va Prolia biosimilaridir, bu saratonning ma'lum turlariga ega bemorlarda suyak sinishini, orqa miya siqilishini va radioterapiya yoki suyak jarrohligi zaruriyatini oldini olish uchun, shuningdek suyak yo'qotilishini oldini olish va suyak massasini oshirish uchun mo'ljallangan. Bundan tashqari, u revmatoid artrit, psoriatik artrit, yarali kolit va boshqa ko'rsatmalarni o'z ichiga olgan turli xil yallig'lanishlarni davolash uchun Simponi va Simponi Aria biosimilarini, AVT05; o'rtacha yoki og'ir yarali kolit va o'rtacha yoki og'ir darajada faol Kron kasalligi bo'lgan kattalar bemorlarni davolash uchun Entyvio mahsulotining biosimilarini, AVT16; allergik astma, surunkali spontan ürtiker (CSU) va burun poliplarini davolash uchun Xolair biosimilarini, AVT23; va dastlabki rivojlanish bosqichida bo'lgan Keytruda mahsulotining biosimilarini, AVT33 taklif etadi. Alvotech 2013 yilda tashkil etilgan va Lyuksemburg, Lyuksemburgda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Balaji Venkataramanan Prasad M.D. | Chief Strategy Officer |
| Mr. Anthony M. Maffia III | Chief Quality & Regulatory Officer |
| Mr. Benedikt Stefansson | Vice President of Investor Relations & Global Communications |
| Mr. Joseph E. McClellan | Chief Operating Officer |
| Mr. Vilhelm Robert Wessman | Founder, CEO & Executive Chairman |
| Ms. Agne Pasko | Vice President & Head of Business Development |
| Ms. Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-19 | 6-K | f6k_031826.htm |
| 2026-02-02 | 6-K | f6k_020226.htm |
| 2026-01-29 | 6-K | f6k_012826.htm |
| 2026-01-07 | 6-K | f6k_010726.htm |
| 2026-01-06 | 6-K | f6k_010626.htm |
| 2026-01-02 | 6-K | f6k_010226.htm |
| 2025-12-23 | 6-K | f6k_122325.htm |
| 2025-12-19 | 6-K | f6k_121925.htm |
| 2025-12-17 | 6-K | f6k_121725.htm |
| 2025-11-24 | 6-K | f6k_112425.htm |
| Ms. Linda Jonsdottir | Chief Financial Officer |
| Ms. Sarah Macleod | Head of Global Communications |
| Ms. Tanya Zharov | General Counsel |